CSF2 and rheumatoid arthritis: We will review recent evidence for inflammatory mediators that are novel therapeutic targets, e.g. GM‐CSF, and describe novel functions of well‐described inflammatory mediators, e.g. TNF, that could explain their contribution to the chronicity of RA.